Dyslipidemia is a key link in the pathogenesis of metabolic syndrome in HCV infection

• Maxim S. Bokhonov
• Anastasia A. Koklyushkina
• Ivan G. Sitnikov

Abstract

Violation of lipid metabolism in hepatitis C is one of the links of the metabolic syndrome. An important component of the metabolic syndrome in patients with chronic hepatitis C is the risk of developing insulin resistance.

The aim is to analyze the published results on the role of lipid metabolism disorders in the pathogenesis of hepatitis C and metabolic syndrome.

Material and methods. The articles were searched in the databases PubMed, Elsevier, Scopus, Web of Science, eLibrary, by keywords: viral hepatitis C, pathogenesis, life cycle, metabolic syndrome, insulin resistance. A total of 45 publications were studied, and 18 papers were selected for analysis.

Results and discussion. A review of scientific studies on lipid metabolism disorders in hepatitis C. It has been shown that patients with chronic hepatitis C have a higher risk of developing insulin resistance.

Conclusion. Patients with chronic hepatitis C have a higher risk of developing insulin resistance than patients with other liver diseases. Changes in the structure of genes encoding enzymes that regulate lipid metabolism may be important in the formation of metabolic syndrome in patients with chronic hepatitis C.

Keywords: metabolic syndrome, HCV-infection, chronic hepatitis C, lipoproteins, cholesterol, lipid metabolism, insulin resistance

References

1. Chaudhari R., Fouda S., Sainu A., Pappachan J.M. Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021; 27: 1267–82.
2. d’Avigdor W.M.H., Budzinska M.A., Lee M., Lam R., Kench J., Stapelberg M., et al. Virus genotype-dependent transcriptional alterations in lipid metabolism and inflammation pathways in the hepatitis C virus-infected liver. Sci Rep. 2019; 9: 10596.
3. Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol. 2021; 27: 1006–21.
4. Valiakou V., Eliadis P., Karamichali E., Tsitsilonis O., Koskinas J., Georgopoulou U., et al. Differential expression of the host lipid regulators ANGPTL-3 and ANGPTL-4 in HCV infection and treatment. Int J Mol Sci. 2021; 22: 7961.
5. Iossa D., Vitrone M., Gagliardi M., Falco E., Ragone E., Zampino R., et al. Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment. Ann Transl Med. 2021; 9: 35.
6. Kumar A., Hossain R.A., Yost S.A., Bu W., Wang Y., Dearborn A.D., et al. Structural insights into hepatitis C virus receptor binding and entry. Nature. 2021; 598: 521–5.
7. Elabd N.S., Tayel S.I., Elhamouly M.S., Hassanein S.A., Kamaleldeen S.M., Ahmed F.E., et al. Evaluation of microRNA-122 as a biomarker for chronic hepatitis c infection and as a predictor for treatment response to direct-acting antivirals. Hepat Med. 2021; 13: 9–23.
8. Panigrahi M., Thibault P.A., Wilson J.A. MicroRNA 122 affects both the initiation and the maintenance of hepatitis C virus infections. J Virol. 2022; 96: e0190321.
9. Olzmann J.A., Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019; 20: 137–55.
10. Cosset F.L., Mialon C., Boson B., Granier C., Denolly S. HCV interplay with lipoproteins: inside or outside the cells? Viruses. 2020; 12: 434.
11. Bliznyuk S.A., Bubnova M.G., Ezhov M.V. Familial hypercholesterolemia: current status of the problem, treatment, and prevention. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (5): 247–51. (in Russian)
12. Ferreira L.D., Pulawa L.K., Jensen D.R., Eckel R.H. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes. 2001; 50 (5): 1064–8. DOI: https://doi.org/10.2337/diabetes.50.5.1064 PMID: 11334409.
13. Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Afdhal N.H., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007; 45: 80–7. DOI: https://doi.org/10.1002/hep.21455
14. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., Salmerón J., Diago M., Fernández-Rodríguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005; 128 (3): 636–41.
15. Harrison S.A., Ramrahiani S., Brant E.M., Anbari M.A., Cortese C., Bacon B.R. Insulin resistance in patients with chronic hepatitis C: etiology and impact of treatment. Clin Gastroenterol Hepatol. 2008; 6 (8): 864–6. DOI: https://doi.org/10.1016/j.cgh.2008.03.024
16. Mendivil C.O., Rimm E.B., Furtado J., Sacks F.M. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc. 2013; 2 (3): e000130.
17. Sitnikov I.G., Rozina V.L. Metabolic disorders and changes in body composition as risk factors for the progression of chronic viral hepatitis C. Vestnik IvGMA [Bulletin of IvGMA]. 2019; (2). URL: https://cyberleninka.ru/article/n/metabolicheskie-narusheniya-i-izmeneniya-sostava-tela-kak-faktory-riska-progressirovaniya-hronicheskogo-virusnogo-gepatita-s (date of access February 05, 2024). (in Russian)
18. Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008; 134: 416–23. DOI: https://doi.org/10.1053/j.gastro.2007.11.010

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)